Skip to main content
Top
Published in: Internal and Emergency Medicine 4/2020

01-06-2020 | Erythema Nodosum | IM - ORIGINAL

Clinical features and management of venous thromboembolism in patients with Behçet’s syndrome: a single-center case–control study

Authors: Neera Toledo-Samaniego, Francisco Galeano-Valle, Blanca Pinilla-Llorente, Jorge Del-Toro-Cervera, Alberto Marra, Marco Proietti, Pablo Demelo-Rodríguez

Published in: Internal and Emergency Medicine | Issue 4/2020

Login to get access

Abstract

Almost one third of patients with Behçet's syndrome (BS) display vascular involvement. However, data regarding the prevalence and management of venous thromboembolism (VTE) in BS are scanty. We assessed the differential characteristics between patients with and without VTE and the factors associated with VTE incidence. A case–control study in a cohort of patients with BS was performed. 57 patients were included (56.1% women) with a mean follow-up of 10.56 (± 10.7) years. Mean age at diagnosis of BS and diagnosis of the first VTE episode was 34.7 (± 12.1) and 31.2 (± 8.9) years, respectively. Erythema nodosum (OR 4.6, CI 95% 1.2–18.1) and fever (OR 8.2, CI 95% 1.6–42.1) were associated with a higher risk of VTE. 26 episodes of VTE were registered in 12/57 (21%) patients. 83.3% of patients were not diagnosed with BS when the first episode of VTE occurred and, among them, the episode of VTE led to the diagnosis of BS in 40% of cases. Half of patients had at least one VTE recurrence. The absence of immunosuppressive treatment was associated with a higher risk of developing a first episode of VTE (OR 20 CI 95% 19.2–166.6). All patients were treated with anticoagulation and 75% were treated with immunosuppressants after the first VTE event. The diagnosis of VTE usually precedes that of BS, with a high frequency of VTE recurrence. Erythema nodosum and fever were associated with a higher risk of VTE, while the immunosuppressants showed a protective role for the development of VTE.
Literature
1.
go back to reference Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14:107–119 (Erratum in Nat Rev Rheumatol. 2018 14:119) CrossRef Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14:107–119 (Erratum in Nat Rev Rheumatol. 2018 14:119) CrossRef
2.
go back to reference Seyahi E (2016) Behçet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol [Internet] 30(2):279–295CrossRef Seyahi E (2016) Behçet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol [Internet] 30(2):279–295CrossRef
3.
go back to reference Emmi G, Silvestri E, Squatrito D, Prisco D, Emmi L (2014) Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med 9:257–265CrossRef Emmi G, Silvestri E, Squatrito D, Prisco D, Emmi L (2014) Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med 9:257–265CrossRef
4.
go back to reference Seyahi E (2019) Phenotypes in Behçet’s syndrome. Intern Emerg Med 14(5):677–689CrossRef Seyahi E (2019) Phenotypes in Behçet’s syndrome. Intern Emerg Med 14(5):677–689CrossRef
5.
go back to reference Emmi G, Bettiol A, Silvestri E, Di G, Matteo S, Claudia B et al (2018) Vascular Behçet’s syndrome: an update. Intern Emerg Med 14(5):645–652CrossRef Emmi G, Bettiol A, Silvestri E, Di G, Matteo S, Claudia B et al (2018) Vascular Behçet’s syndrome: an update. Intern Emerg Med 14(5):645–652CrossRef
6.
go back to reference Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Behçet syndrome a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Behçet syndrome a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef
7.
go back to reference Fabiani C, Vitale A, Orlando I, Sota J, Capozzoli M, Franceschini R et al (2017) Quality of life impairment in Behçet’s disease and realationship with disease activity: a prospective study. Intern Emerg Med 12:947–955CrossRef Fabiani C, Vitale A, Orlando I, Sota J, Capozzoli M, Franceschini R et al (2017) Quality of life impairment in Behçet’s disease and realationship with disease activity: a prospective study. Intern Emerg Med 12:947–955CrossRef
8.
go back to reference Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P (2016) Behçet's disease physiopathology: a contemporary review. Auto Immun Highlights 7:4CrossRef Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P (2016) Behçet's disease physiopathology: a contemporary review. Auto Immun Highlights 7:4CrossRef
9.
go back to reference Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C (2019) Behçet’s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol 10:1085CrossRef Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C (2019) Behçet’s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol 10:1085CrossRef
10.
go back to reference Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D et al (2016) Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation 133:302–311CrossRef Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D et al (2016) Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation 133:302–311CrossRef
11.
go back to reference Becatti M, Emmi G, Bettiol A, Silvestri E, Scala G, Taddei N et al (2019) Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clin Exp Imunol. 195(3):322–333CrossRef Becatti M, Emmi G, Bettiol A, Silvestri E, Scala G, Taddei N et al (2019) Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clin Exp Imunol. 195(3):322–333CrossRef
12.
go back to reference Mantovani A, Cassatella MA, Constatini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Inmunol 11:519–531CrossRef Mantovani A, Cassatella MA, Constatini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Inmunol 11:519–531CrossRef
13.
go back to reference Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77(6):808–818PubMed Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77(6):808–818PubMed
14.
go back to reference Fei Y, Li X, Lin S, Song X, Wu O, Zhu Y et al (2013) Major vascular involvement in Behçet's disease: a retrospective study of 796 patients. Clin Rheumatol 32:845–852CrossRef Fei Y, Li X, Lin S, Song X, Wu O, Zhu Y et al (2013) Major vascular involvement in Behçet's disease: a retrospective study of 796 patients. Clin Rheumatol 32:845–852CrossRef
15.
go back to reference Seyahi E, Yazici H (2015) Behçet’s syndrome : pulmonary vascular disease. Curr Opin Rheumatol 27:18–23CrossRef Seyahi E, Yazici H (2015) Behçet’s syndrome : pulmonary vascular disease. Curr Opin Rheumatol 27:18–23CrossRef
16.
go back to reference International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
17.
go back to reference Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M et al (2014) International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRef Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M et al (2014) International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRef
18.
go back to reference Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Ríos-Fernández R, Nieto J et al (2018) Venous thrombosis and relapses in patients with Behçet’s disease. Descriptive analysis from Spanish network of Behçet’s disease (REGEB cohort). Autoimmune Diseases Study Group (GEAS). Clin Exp Rheumatol 36((6 Suppl 115)):40–44PubMed Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Ríos-Fernández R, Nieto J et al (2018) Venous thrombosis and relapses in patients with Behçet’s disease. Descriptive analysis from Spanish network of Behçet’s disease (REGEB cohort). Autoimmune Diseases Study Group (GEAS). Clin Exp Rheumatol 36((6 Suppl 115)):40–44PubMed
19.
go back to reference Alibaz-Oner F, Karadeniz A, Yılmaz S, Balkarlı A, Kimyon G, Yazıcı A et al (2015) Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Med Baltim 94:e494CrossRef Alibaz-Oner F, Karadeniz A, Yılmaz S, Balkarlı A, Kimyon G, Yazıcı A et al (2015) Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Med Baltim 94:e494CrossRef
20.
go back to reference Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z et al (2012) Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 64:2753–2760CrossRef Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z et al (2012) Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 64:2753–2760CrossRef
21.
go back to reference Wu X, Li G, Huang X, Wang L, Liu W, Zhao Y et al (2014) Behçet’s disease complicated with thrombosis a report of 93 Chinese cases. Medicine (Baltimore) 93(28):e263CrossRef Wu X, Li G, Huang X, Wang L, Liu W, Zhao Y et al (2014) Behçet’s disease complicated with thrombosis a report of 93 Chinese cases. Medicine (Baltimore) 93(28):e263CrossRef
22.
go back to reference Tohmé A, Aoun N, El-Rassi B, Ghayad E (2003) Vascular manifestations of Behçet’s disease. Eighteen cases among 140 patients. Joint Bone Spine 70:384–389CrossRef Tohmé A, Aoun N, El-Rassi B, Ghayad E (2003) Vascular manifestations of Behçet’s disease. Eighteen cases among 140 patients. Joint Bone Spine 70:384–389CrossRef
23.
go back to reference Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H et al (2018e) Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatol Oxf 53:2018e22CrossRef Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H et al (2018e) Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatol Oxf 53:2018e22CrossRef
24.
go back to reference Galeano-Valle F, Demelo-Rodriguez P, Álvarez-Sala-Walther L, Pinilla-Llorente B, Echenagusia-Boyra MJ, Rodriguez-Abella H et al (2018) Intracardiac thrombosis in Behçet’s Disease successfully treated with immunosuppressive agents: a case of vascular pathergy phenomenon. Intractable Rare Dis Res 7(1):54–57CrossRef Galeano-Valle F, Demelo-Rodriguez P, Álvarez-Sala-Walther L, Pinilla-Llorente B, Echenagusia-Boyra MJ, Rodriguez-Abella H et al (2018) Intracardiac thrombosis in Behçet’s Disease successfully treated with immunosuppressive agents: a case of vascular pathergy phenomenon. Intractable Rare Dis Res 7(1):54–57CrossRef
25.
go back to reference Oblitas CM, Galeano-Valle F, Toledo-Samaniego N, Pinilla-Llorente B, Del Toro-Cervera J, Álvarez-Luque A et al (2019) Budd-Chiari syndrome in Behçet's disease successfully managed with immunosuppressive and anticoagulant therapy: a case report and literature review. Intractable Rare Dis Res 8(1):60–66CrossRef Oblitas CM, Galeano-Valle F, Toledo-Samaniego N, Pinilla-Llorente B, Del Toro-Cervera J, Álvarez-Luque A et al (2019) Budd-Chiari syndrome in Behçet's disease successfully managed with immunosuppressive and anticoagulant therapy: a case report and literature review. Intractable Rare Dis Res 8(1):60–66CrossRef
26.
go back to reference Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS (2008) Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 27:201–205CrossRef Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS (2008) Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 27:201–205CrossRef
27.
go back to reference Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E (2012) Major vessel thrombosis in Behçet’s disease: the dilemma of anticoagulant therapy—the approach of rheumatologists from different countries. Clin Exp Rheumatol 30:735–740PubMed Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E (2012) Major vessel thrombosis in Behçet’s disease: the dilemma of anticoagulant therapy—the approach of rheumatologists from different countries. Clin Exp Rheumatol 30:735–740PubMed
28.
go back to reference Hamuryudan V, Er T, Seyahi E, Akman C, Tüzün H, Fresko I et al (2004) Pulmonary artery aneurysm in Behçet syndrome. Am J Medd 117:867–870CrossRef Hamuryudan V, Er T, Seyahi E, Akman C, Tüzün H, Fresko I et al (2004) Pulmonary artery aneurysm in Behçet syndrome. Am J Medd 117:867–870CrossRef
Metadata
Title
Clinical features and management of venous thromboembolism in patients with Behçet’s syndrome: a single-center case–control study
Authors
Neera Toledo-Samaniego
Francisco Galeano-Valle
Blanca Pinilla-Llorente
Jorge Del-Toro-Cervera
Alberto Marra
Marco Proietti
Pablo Demelo-Rodríguez
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 4/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02237-7

Other articles of this Issue 4/2020

Internal and Emergency Medicine 4/2020 Go to the issue

Acknowledgement to Referees

Reviewers 2019

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine